Healthcare Partnerships Emerald has already secured collaboration with academic researchers and industry partners (including Aspen Neuroscience and Torrey Pines), working with doctors, pharma, biotech, providers, and insurers to develop digital biomarkers and support disease management. Use this momentum to pursue new hospital networks, medical centers, and research consortia for pilots and multi-site deployments of touchless health analytics.

Neurology Trial Opportunities Recent Parkinson's focused partnerships indicate strong demand for digital health modalities in neurology trials. Position Emerald as a trial-ready sensor platform that can integrate with existing trial ecosystems and data platforms, appealing to pharma, biotech, CROs, and neurology research groups.

Digital Biomarker Monetization With revenue in the tens of millions, there is potential to expand offerings to hospitals and health insurers via disease management programs and remote monitoring bundles, selling as a platform plus services for digital biomarker development, analytics, and clinical decision support.

Regulatory and Privacy Off-body sensing involves sensitive health data. Emphasize HIPAA/regulatory readiness and robust data governance to reassure providers, payers, and researchers, unlocking opportunities in compliant patient monitoring, remote trials, and real-world evidence programs.

Platform Integrations Capitalize on the ability to integrate with EMR/EHR systems, telehealth platforms, and trial data ecosystems. Pursue partnerships with healthcare IT vendors and data analytics platforms to embed Emerald’s digital biomarkers into existing clinical workflows and research pipelines, including collaboration with Rune Labs.